413 results match your criteria Atherosclerosis Supplements[Journal]


Cardiovascular risk factors in patients with premature cardiovascular events attending the University of Dresden Lipid Clinic.

Atheroscler Suppl 2019 Dec;40:94-99

Department of Internal Medicine III, Faculty of Medicine Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany. Electronic address:

Objectives: Despite improved treatment, premature cardiovascular (CV) events remain a major health problem. Aim of this study was to evaluate the patterns of risk factors in patients with premature CV events.

Methods: CV risk factors (CVRF) were evaluated in 130 patients with a history of CV events (myocardial infarction, stroke, limb ischemia, stent and bypass intervention in any vessel bed) under 50 years of age attending our lipid clinic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.044DOI Listing
December 2019

Serum uric acid and left ventricular geometry pattern in obese children.

Atheroscler Suppl 2019 Dec;40:88-93

Medical Faculty, University of Nis, Nis, Serbia.

Background: Relative importance of traditional and non-traditional components of metabolic syndrome (MetSy) as risk factors for subclinical target organ damage in obese children is still under investigation. Recent studies highlight the role of serum uric acid (SUA) as an emerging non-traditional independent risk factor which correlates with obesity, MetSy, type 2 diabetes, preclinical cardiac and extracardiac organ damage, as well as cardiovascular events.

Aims: To study the relationship between SUA and left ventricular geometry pattern in obese children with or without MetSy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.035DOI Listing
December 2019

Lipoprotein apheresis in Austria - Reduction of cardiovascular events by regular lipoprotein apheresis treatment.

Atheroscler Suppl 2019 Dec 17;40:8-11. Epub 2019 Aug 17.

Athos Institute, Institute for Diagnosis and Treatment of Lipid Disorders and Atherosclerosis, Vienna, Austria; Sigmund Freud University, Department of Lipid Metabolism, Faculty of Medicine, Vienna, Austria.

Background: In Austria, about 12 patients per 1 million inhabitants are treated currently with lipoprotein (LP-) apheresis. In 2016 it has been suggested, that about 5000 patients were treated worldwide with LP-apheresis, more than half of them in Germany. Regular LP-apheresis aims to decrease apolipoprotein B-rich lipoproteins and to reduce cardiovascular events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.025DOI Listing
December 2019

Efficiency and problems of statin therapy in patients with heterozygous familial hypercholesterolemia.

Atheroscler Suppl 2019 Dec 17;40:79-87. Epub 2019 Aug 17.

Lipidology and Lipoprotein Apheresis Center, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.

Familial hypercholesterolemia (FH) is associated with a very high risk of cardiovascular complications and the need for an early aggressive lipid-lowering therapy. The achievement of lipid target levels is often an extremely difficult task in these patients.

Aims: to analyze sex and age structure of ischemic heart disease (IHD) in patients with a definite, possible and probable FH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.029DOI Listing
December 2019

Apheresis as emerging treatment option in severe early onset preeclampsia.

Atheroscler Suppl 2019 Dec 17;40:61-67. Epub 2019 Aug 17.

Institute of Clinical Chemistry and Laboratory Medicine, Medical Center - University of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany; Faculty of Medicine, University of Freiburg, Germany.

Based on an early suggestion by Winkler et al. 2003 and a subsequent successful study by Wang et al. 2006 using lipid apheresis (LA) in 9 patients with preeclampsia to prolong pregnancies, the use of apheresis as therapeutic option in severe early onset preeclampsia has received increasing attention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.028DOI Listing
December 2019

Optical coherence tomography of retinal and choroidal layers in patients with familial hypercholesterolaemia treated with lipoprotein apheresis.

Atheroscler Suppl 2019 Dec;40:49-54

Department of Sense Organs, Faculty of Medicine and Dentistry, Sapienza University of Rome, Italy. Electronic address:

Purpose: Detect and quantify morpho-functional alterations of the retina and choroid in patients affected by familial hypercholesterolemia (FH) treated with lipoprotein apheresis (LA) using optic coherence tomography (OCT) and optic coherence tomography-angriography (OCTA).

Design: Observational study.

Subjects: To be diagnosed: A group of 20 patients (40 eyes) being clinically and genetically diagnosed as FH and under treatment (FH-Group)", for at least 2 years, was compared to a control group of 20 healthy subjects (40 eyes), with a normal lipid profile and no ocular disease (CT-Group). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.031DOI Listing
December 2019

One year follow-up of patients with reduced left ventricular ejection fraction (LVEF) on lipoprotein apheresis.

Atheroscler Suppl 2019 Dec;40:44-48

Institute for Diagnosis and Treatment of Lipid Disorders and Atherosclerosis (ATHOS), Austria; Department of Lipid Metabolism, Faculty of Medicine, Sigmund Freud University, Vienna, Austria; Isotopix, Institute for Nuclear Medicine, Vienna, Austria. Electronic address:

Background: Left ventricular ejection fraction (LVEF) is a valuable measure to assess left ventricular systolic function. Lipid lowering therapy by statins has been shown to have an impact on LVEF already after a 6 months treatment. Higher doses of statins have been claimed to be more effective as compared to a conventional one and even a difference between lipophilic and hydrophilic compounds has been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.039DOI Listing
December 2019

Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis.

Atheroscler Suppl 2019 Dec;40:38-43

Lipidology, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany.

Purpose: We analyzed efficacy and safety of PCSK9i in patients undergoing lipoprotein apheresis (LA) and in patients treated at our outpatient department for metabolic disorders.

Methods: The medical records of 40 LA patients, taking PCSK9i were reviewed with respect to LDL-cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) lowering as well as occurrence of adverse events. Furthermore, we analyzed the data of 152 patients of our outpatient department, undergoing PCSK9i therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.045DOI Listing
December 2019

Short- and long-term effects of lipoprotein apheresis on plasma hormones in patients with therapy-resistant dyslipidemia.

Atheroscler Suppl 2019 Dec;40:30-37

Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany. Electronic address:

Background And Aims: Lipoprotein apheresis (LA) is a highly effective method to improve the clinical and metabolic situation in patients with therapy-resistant disorders of lipid metabolism. Cholesterol is the substrate for the synthesis of all steroid hormones. If repeated massive reduction of LDL-cholesterol may interfere with human adrenal steroidogenesis, and could become clinically relevant is unknown, so far. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.042DOI Listing
December 2019

Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?

Atheroscler Suppl 2019 Dec;40:23-29

Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.

Background: Although lipid-lowering drugs, especially statins, and recently also PCSK9 inhibitors can reduce LDL cholesterol (LDL-C) and decrease the risk for cardiovascular disease (CVD) including coronary artery disease (CAD) events most efficiently, only 5-10% of high-risk cardiovascular patients reach the target values recommended by international guidelines. In patients who cannot be treated adequately by drugs it is possible to reduce increased LDL-C and/or lipoprotein(a) (Lp(a)) values by the use of lipoprotein apheresis (LA) with the potential to decrease severe CVD events in the range of 70%->80%. Even in Germany, a country with well-established reimbursement guidelines for LA, knowledge about this life-saving therapy is unsatisfactory in medical disciplines treating patients with CVD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.038DOI Listing
December 2019

Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis.

Atheroscler Suppl 2019 Dec;40:17-22

Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany.

Lipoprotein(a) (Lp(a)) consists of an LDL particle whose apolipoprotein B (apoB) is covalently bound to apolipoprotein(a) (apo[a]). An increased Lp(a) concentration is a causal, independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and a predictor of incident or recurrent cardiovascular events. Although Lp(a) was first described as early as 1963, only the more recent results of epidemiological, molecular, and genetic studies have led to this unequivocal conclusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.037DOI Listing
December 2019
2.293 Impact Factor

Lipoprotein apheresis - Shortening of treatment intervals reduces cardiovascular events: Case reports.

Atheroscler Suppl 2019 Dec 17;40:125-130. Epub 2019 Aug 17.

Athos Institute, Institute for Diagnosis and Treatment of Lipid Disorders, Vienna, Austria; Sigmund Freud University, Department of Lipid Metabolism, Faculty of Medicine, Vienna, Austria.

Background: Lipoprotein (Lp-) apheresis is a life-long therapy, usually performed in weekly intervals. In some cases, however, atherosclerotic disease progresses despite adequate therapy with weekly Lp-apheresis and maximal lipid lowering medication. In an attempt to improve the effectiveness of therapy, we temporarily shortened treatment intervals of Lp-apheresis in patients with elevated lipoprotein(a) (Lp(a)) and further progression of coronary atherosclerosis despite weekly Lp-apheresis and maximal lipid lowering medication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.024DOI Listing
December 2019

Homozygous familial hypercholesterolaemia in childhood - The first case report in Southeast Europe.

Atheroscler Suppl 2019 Dec 17;40:122-124. Epub 2019 Aug 17.

Pediatric Clinic, University Clinical Center of Kosovo, Prishtina, Kosovo.

Homozygous familial hypercholesterolaemia (HoFH) is the rare, severe, but treatable disease characterised by exceedingly high levels of low-density lipoprotein cholesterol (LDL-C) and subsequent premature coronary heart disease. Of note, HoFH detection rate and patient access to healthcare and treatment modalities still differ considerably across EU countries. To our current knowledge, there are still no published reports describing HoFH in the paediatric population of Southeastern Europe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.034DOI Listing
December 2019

Influence of lipoprotein apheresis on circulating plasma levels of miRNAs in patients with high Lp(a).

Atheroscler Suppl 2019 Dec;40:12-16

Centre for Experimental Medicine - Laboratory for Atherosclerosis Research, Institute for Clinical and Experimental Medicine, Czech Republic; Department of Internal Medicine, 2nd Medical Faculty, Charles University, Prague, Czech Republic.

Background: Lipoprotein apheresis (LA) is a well-established therapy for lowering lipid levels in serious cases of dyslipidaemia, including high levels of lipoprotein(a) [Lp(a)]. This method lowers both LDL cholesterol and Lp(a) by more than 60% in most of patients; however, because randomized clinical studies could be extremely difficult, also other markers of the effect of this procedures on vascular health are of importance. Therefore, in addition to changes in plasma lipids and Lp(a) during LA, we also analysed the response of biomarkers associated with vascular integrity: small non-coding microRNAs (miRNAs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.036DOI Listing
December 2019

A successful term pregnancy with severe hypertriglyceridaemia and acute pancreatitis. Clinical management and review of the literature.

Atheroscler Suppl 2019 Dec 17;40:117-121. Epub 2019 Aug 17.

Extracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Immunohematology and Transfusion Medicine, Department of Molecular Medicine, "Sapienza" University of Rome, "Umberto I" Hospital, Rome, Italy.

Background And Aims: Acute hyperlipidaemic pancreatitis (HP) may develop in pregnancy in patients with genetic predisposition. There are no accepted guidelines for the management of this rare but life-threatening condition in pregnancy. Plasma exchange (PEX) was suggested as a suitable option to treat HP in pregnancy; however, further evidence from case reports/case series are needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.032DOI Listing
December 2019

A complicated pregnancy in homozygous familial hypercholesterolaemia treated with lipoprotein apheresis: A case report.

Atheroscler Suppl 2019 Dec 17;40:113-116. Epub 2019 Aug 17.

Extracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Immunohaematology and Transfusion Medicine, Department of Molecular Medicine, "Sapienza" University of Rome, "Umberto I" Hospital, Rome, Italy.

Background And Aims: During pregnancy total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels increase significantly and lipoprotein apheresis (LA) is considered the most effective therapy in homozygous familial hypercholesterolaemia (HoFH) for modulating lipid and lipoprotein levels and reducing maternal and foetal complications.

Clinical Case: A primigravida 28 years old Caucasian female patient, previously diagnosed as to be HoFH, was admitted at our outpatient service at the beginning of pregnancy.

Methods: The patient was continuously submitted to LA every two weeks without foetal complication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.033DOI Listing
December 2019

Kidney and liver are the main organs of expression of a key metabolic enzyme alanine:glyoxylate aminotransferase 2 in humans.

Atheroscler Suppl 2019 Dec;40:106-112

University Center for Vascular Medicine & Department of Medicine III - Section Angiology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. Electronic address:

Background: The metabolic syndrome is a cluster of cardiovascular risk factors and is highly predictive for development of cardiovascular diseases. An association between elevated plasma levels of the endogenous inhibitor of nitric oxide synthases asymmetric dimethylarginine (ADMA) and risk of cardiovascular diseases has been demonstrated in numerous epidemiological studies. ADMA can be catabolized by dimethylarginine dimethylaminohydrolase (DDAH) or metabolized through a much less understood alternative pathway by alanine:glyoxylate aminotransferase 2 (AGXT2) with the formation of α-keto-δ-(N,N-dimethylguanidino)valeric acid (ADGV). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.041DOI Listing
December 2019

ADMA elevation does not exacerbate development of diabetic nephropathy in mice with streptozotocin-induced diabetes mellitus.

Atheroscler Suppl 2019 Dec;40:100-105

Division of Nephrology, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.

Background And Aims: Cardiovascular disease is nowadays the major cause of mortality and morbidity worldwide. The risk of developing cardiovascular disease is significantly increased in patients with diabetic nephropathy. It has been suggested that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthases (NOS), may play an important role in the pathogenesis of diabetic nephropathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.040DOI Listing
December 2019

Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.

Atheroscler Suppl 2019 Dec;40:1-7

Lipidology and Center for Extracorporeal Treatment, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany, Fetscherstr. 74, 01307, Dresden, Germany.

An elevation of lipoprotein(a) (Lp(a)) is an internationally recognized atherogenic risk factor, documented in epidemiological studies, in studies with Mendelian randomization and in genome-wide association studies (GWAS). At present, no drug is available to effectively reduce its concentration. In Germany, an elevation of Lp(a) associated with progressive cardiovascular diseases is officially recognized as an indication for a lipoprotein apheresis (LA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.043DOI Listing
December 2019

Immunoadsorption in nephrotic syndrome: Where are we now and where are we going from here?

Atheroscler Suppl 2019 Dec 17;40:55-60. Epub 2019 Aug 17.

Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.

Idiopathic nephrotic syndrome (INS) is characterized by three different entities, namely minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS) and membranous nephropathy (MN). While there is an increasing understanding of primary MN with the discovery of antibodies directed against phospholipase A2 receptor (PLA2R Ab) and thrombospondin type 1 domain-containing 7A, circulatory factors causative of inducing MCD and FSGS remain in part elusive. Extracorporeal treatment forms (mostly plasma exchange) have been reserved for patients with either a disease course refractory to commonly prescribed immunosuppressive drugs or to patients with recurrence after kidney transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.027DOI Listing
December 2019
1 Read

Statin-induced muscular side effects at rest and exercise - An anatomical mapping.

Atheroscler Suppl 2019 Dec 17;40:73-78. Epub 2019 Aug 17.

Athos Institute, Institute for Diagnosis and Treatment of Lipid Disorders, Vienna, Austria; Sigmund Freud University, Department of Lipid Metabolism, Faculty of Medicine, Vienna, Austria.

Background And Aims: Muscle-related symptoms with or without creatine kinase (CK) elevation are common adverse effects associated with statin use. Symptoms are ranging from benign myalgia to myositis and in rare cases to rhabdomyolysis. The aim was to characterize and describe muscular side effects and create an anatomical frequency mapping. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15675688193004
Publisher Site
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.026DOI Listing
December 2019
3 Reads

Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion.

Atheroscler Suppl 2019 Dec 17;40:68-72. Epub 2019 Aug 17.

Department of Nephrology, University of Heidelberg, Heidelberg, Germany.

Objective: In recent studies, semi-selective compared to antigen-specific immunoadsorption (IA) columns showed comparable effectiveness in anti-A/B antibody removal before incompatible living donor kidney transplantation. Semi-selective columns allow a greater number of IA treatments at lower costs. They are also capable of removing potentially harmful human leukocyte antigen alloantibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.030DOI Listing
December 2019

Achilles tendon ultrasonography - A useful screening tool for cardiovascular risk estimation in patients with severe hypercholesterolemia.

Atheroscler Suppl 2019 Mar 29;36:6-11. Epub 2019 Jan 29.

Children's Hospital, Vilnius University Hospital Santaros Klinikos, Lithuania.

Background And Aims: Achilles tendon lesions have long been associated with genetic defects in lipid metabolism and increased risk of cardiovascular diseases (CVD). With this study we aimed to evaluate the usefulness of Achilles tendon ultrasonography in identifying people at greater risk among subjects with severe hypercholesterolemia (SH) in a high-risk population.

Methods: During the period of 2016-2017 a total of 213 participants were enrolled in this case-control study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.002DOI Listing
March 2019
18 Reads

Investigating the association between familial hypercholesterolemia and perceived depression.

Atheroscler Suppl 2019 Mar 29;36:31-36. Epub 2019 Jan 29.

Department of Internal Medicine and Cardiovascular Center, National Taiwan University Hospital, Taipei, 10002, Taiwan; Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, 10020, Taiwan; Department of Environmental and Occupational Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taiwan. Electronic address:

Background And Aims: Inherited familial hypercholesterolemia (FH) increases cardiovascular risks, but perceived depression in FH is unknown. This study aims to explore the association between the FH and perceived depression.

Methods: This study was a hospital-based design, we started to recruit clinical diagnosis of phenotypic FH since 2014 for the Ten Countries Study in the Asia-Pacific region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.007DOI Listing
March 2019
3 Reads

Variable expression and penetrance in Portuguese families with Familial Hypercholesterolemia with mild phenotype.

Authors:
I M Gaspar A Gaspar

Atheroscler Suppl 2019 Mar;36:28-30

Metabolic Unit, Pediatric Department, Santa Maria Hospital, Lisboa, Portugal.

Familial hypercholesterolemia is an Mendelian dominant disorder characterized by defects of the low density lipoprotein receptor (LDLR) that result in a defective removal of LDL from plasma, which promotes deposition of cholesterol in the skin (xanthelasma), tendons (xanthomas), and arteries (atherosclerosis). Diagnosis severe clinical phenotype FH with Dutch Lipid Clinic Network Criteria, encompassing history of premature ASCVD, tendon xanthomas, and a family history of hypercholesterolemia and premature ASCVD in relatives is rare in the Portuguese FH patients. There is a variability of the phenotype in FH individuals with clinical diagnosis or genetic mutation (carriers and patients) probably due to environmental factors in the last century, a Mediterranean diet, or a diet without fat food, trans fat food, no smoking, no sedentary life that can interfere with our metabolism, or are consequences of polygenic, epigenetic, acquired defects, modifiers genes and beta-globin asymptomatic carriers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.006DOI Listing
March 2019
18 Reads

Establishing a familial hypercholesterolaemia register - The first year.

Authors:
Myra Tilney

Atheroscler Suppl 2019 Mar 2;36:24-27. Epub 2019 Feb 2.

Department of Medicine, Faculty of Medicine and Surgery, Mater Dei Hospital, University of Malta, B'kara Bypass, Malta; Dept of Primary Care & Public Health, School of Public Health, 319, Global eHealth Unit, Imperial College London, Reynolds Bldg, St Dunstan's Rd, London, W6 8RP, UK. Electronic address:

Background And Aims: Familial hypercholesterolemia (FH) is an autosomal dominant condition raising the risk of premature cardiovascular disease up to twentyfold.[1] [2] It is under-diagnosed and undertreated, in spite of availability of effective treatment. Registers are recommended to assist in the recognition and improvement of the condition since treatment reduces morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.005DOI Listing
March 2019
5 Reads

Percutaneous coronary intervention for a Chinese familial hypercholesterolemia homozygous under the guidance of optical coherence tomography.

Atheroscler Suppl 2019 Mar;36:19-23

Beijing Anzhen Hospital, Capital Medical University - Beijing Institute of Heart, Lung and Blood Vessel Diseases, 100029, China; Department of Atherosclerosis, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. Electronic address:

Homozygous familial hypercholesterolemia developed into severe cardiovascular consequences early. Untreated HoFH usually cannot survive over 30 years old. Acute coronary syndrome(ACS) caused by plaque rupture is one of the main causes of death in HoFH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.004DOI Listing
March 2019
6 Reads
2.293 Impact Factor

Familial hypercholesterolemia in China half a century: A review of published literature.

Atheroscler Suppl 2019 Mar 29;36:12-18. Epub 2019 Jan 29.

Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases Beijing, 100029, China; Department of Atherosclerosis, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. Electronic address:

Aims: To investigate the status of familial hypercholesterolemia (FH) research and the characteristics of patients with FH in China.

Methods: Published papers in Chinese or English language from PubMed, SinoMed and CNKI databases from 1971 to March 2018 were searched using 'Familial hypercholesterolemia', 'Chinese' and 'Han' as keywords. A systematic review of studies on familial hypercholesterolemia was then conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.003DOI Listing
March 2019
6 Reads

The frequency of familial hypercholesterolemia amongst patients in the outpatient clinic of the tertiary specialized cardiology center in Kyrgyzstan.

Atheroscler Suppl 2019 Mar 30;36:1-5. Epub 2019 Jan 30.

Kyrgyz State Medical Academy Named After I.K.Akhunbaev, 720020, 92, Akhunbaeva Str, Bishkek, Kyrgyzstan; National Center of Cardiology and Internal Medicine Named After Academician Mirrakhimov M.M., 720000, 3, Togolok Moldo Str, Bishkek, Kyrgyzstan.

Background: Familial hypercholesterolemia (FH) is frequently underdiagnosed. Prevalence of the FH in Kyrgyzstan is unknown.

Aim: to investigate the prevalence of FH amongst patients in the outpatient settings of the tertiary cardiologic center in Kyrgyzstan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.001DOI Listing
March 2019
5 Reads

Large artery stiffness according to different assessment methods in adult population of St.Petersburg.

Atheroscler Suppl 2018 Sep 24;35:e1-e5. Epub 2018 Aug 24.

Almazov National Medical Research Centre, Saint Petersburg, Russia.

Objective: The aim of the present study was to assess the prevalence of increased arterial stiffness by different diagnostic methods and its association with cardiovascular risk in Russian population-based cohort.

Design And Methods: In terms of Russian epidemiological study ESSE-RF a random selection of 452 apparently healthy Saint-Petersburg inhabitants aged 25-65 years was performed. Fasting lipids, glucose and blood pressure measurements were performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2018.08.001DOI Listing
September 2018
1 Read

Epidemiology of cardiovascular risk factors in two population-based studies.

Atheroscler Suppl 2018 Sep 25;35:e14-e20. Epub 2018 Aug 25.

Epidemiology and Preventive Pharmacology Centre (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9, 20133, Milan, Italy.

We aimed to compare cardiovascular risk factors prevalence in Italy and Russia through cross-sectional database analysis. The study has been based on data from ESSE-RF and from baseline of PLIC study, two population-based epidemiological studies aimed to investigate prevalence of risk factors and evaluating contribution of traditional and new risk factors into morbidity and cardiovascular mortality. A total of 2203 patients with left and right intima-media thickness (IMT) measurements constituted the source population (1205 from PLIC study and 998 from ESSE-RF study). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2018.08.003DOI Listing
September 2018
11 Reads

Notch, BMP and WNT/β-catenin network is impaired in endothelial cells of the patients with thoracic aortic aneurysm.

Atheroscler Suppl 2018 Sep 25;35:e6-e13. Epub 2018 Aug 25.

Almazov Federal Medical Research Centre, Akkuratova, 2, 197341, Saint-Petersburg, Russia; Saint-Petersburg State University, Universitetskaya nab., 7/9, St. Petersburg, 199034, Russia; ITMO University, Institute of Translational Medicine, 49 Kronverksky Pr., St. Petersburg, 197101, Russia. Electronic address:

Cellular and molecular mechanisms of thoracic aortic aneurysm are still not clear and therapeutic approaches are mostly absent. The role of endothelial cells in aortic wall integrity is emerging from recent studies. Although Notch pathway ensures endothelial development and integrity, and NOTCH1 mutations have been associated with thoracic aortic aneurysms, the role of this pathway in aneurysm remains elusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2018.08.002DOI Listing
September 2018
14 Reads
2.293 Impact Factor

Standardization of laboratory and lipid profile evaluation: A call for action with a special focus in 2016 ESC/EAS dyslipidaemia guidelines - Full report.

Atheroscler Suppl 2018 Jun;31:e1-e12

re. Germano de Sousa Group - Centro de Medicina Laboratorial, Pólo Tecnológico de Lisboa, Portugal.

Even with the improvement in lifestyle interventions, a better control of cardiovascular (CV) risk factors, and improvements in CV outcomes, cardiovascular disease (CVD) still persists as the leading cause of morbidity and mortality in Portugal and Europe. Atherogenic dyslipidaemias, namely hypercholesterolaemia, have a crucial and causal role in the development of atherosclerotic CVD. The clinical approach of a patient with dyslipidaemia involves a watchful diagnosis, sustained in lipid and lipoprotein laboratory procedures, which must be harmonized and standardized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2018.04.001DOI Listing
June 2018
5 Reads

Prospective crossover study for a standardized comparison of the dextrane sulfate whole blood and plasma apheresis system in patients with cardiovascular disease and severe dyslipidemia.

Atheroscler Suppl 2017 Nov 1;30:99-107. Epub 2017 Jun 1.

Apheresis Center Rostock (ACR), Nephrocare Rostock GmbH, Nobelstr. 53, 18059 Rostock, Germany. Electronic address:

Background And Aims: The objective of this study was a standardized comparison of the safety and effectiveness of the Kaneka (Kaneka Corporation, Osaka, Japan) whole blood (Liposorber DL-100) and plasma (Liposorber LA-15) lipoprotein apheresis (LA) system to optimize the individual therapy of patients with cardiovascular disease and severe dyslipidemia.

Methods: Six chronic LA patients with a pre-treatment LDL-C < 6 mmol/l in steady state received a total of three treatments with the LA-15 device, followed by three treatments with the DL-100 device or vice versa. To achieve a standardized comparison the treated blood volume for any patient was kept identical for both procedures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.026DOI Listing
November 2017
4 Reads

Impact of double filtration plasmapheresis on adhesion molecules levels in patients with stable coronary heart disease after coronary stenting.

Atheroscler Suppl 2017 Nov 31;30:92-98. Epub 2017 May 31.

Department of Nephrology and Blood Purification, Military Medical Academy, 6, Lebedeva Street, 194044 Saint-Petersburg, Russia.

Objective And Methods: Endothelial dysfunction and inflammatory reaction at the site of damage plays a key role in the formation of neointimal hyperplasia, and in the progression of atherosclerosis. The initiating role in these processes is assigned to adhesion molecules. We studied the dynamics of the level of adhesion molecules soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular adhesion molecule-1 (sVCAM-1), soluble form of the molecule platelet adhesion and endothelial type-1 (sPECAM-1), sL-, sP-, sE-selectins during double filtration plasmapheresis (DFPP) with use of plasma fractionators (PF) Cascadeflo EC-50W and EC-40W (Asahi Kasei Medical Co. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.024DOI Listing
November 2017
8 Reads

The efficacy of anti-PCSK9 antibodies: Results from recent trials.

Atheroscler Suppl 2017 Nov 1;30:9-18. Epub 2017 Jun 1.

Center of Endocrinology, Diabetes and Preventive Medicine (ZEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany. Electronic address:

The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein (LDL) receptor (LDLR) and directs it to the lysosome for degradation. This results in decreased numbers of LDLR available on the cell surface to bind LDL particles and remove them from the circulation and a subsequent increase in circulating LDL-cholesterol (LDL-C) concentrations. Since the role PCSK9 plays in LDL-C metabolism has been discovered in 2003, there have been major efforts in finding efficient and safe methods to inhibit it. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.030DOI Listing
November 2017
3 Reads

Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study.

Atheroscler Suppl 2017 Nov;30:86-91

Department of Internal Medicine and Medical Specialties, University of Rome 'Sapienza', Umberto I Hospital, Rome, Italy.

Background: Hypercholesterolaemia is a major risk factor for cardiovascular disease and requires effective therapy in affected patients. Statins, the mainstay of lipid-lowering therapy, can cause side effects, including myalgia, in some patients. Ezetimibe, is frequently used as an add-on therapy for statins, and is also used as a monotherapy in statin-intolerant patients, however elevations in liver transaminases can occur. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.021DOI Listing
November 2017
11 Reads

Cascade screening for familial hypercholesterolemia: Practical consequences.

Atheroscler Suppl 2017 Nov 1;30:77-85. Epub 2017 Jun 1.

Department of Internal Medicine, Division Vascular Medicine, Erasmus MC, Rotterdam, The Netherlands. Electronic address:

Familial Hypercholesterolemia (FH) is an autosomal dominant disorder mainly caused by mutations in the LDLR gene, resulting in elevated serum cholesterol levels and elevated risk of premature cardiovascular disease (CVD). Timely treatment with lipid lowering medication can lower the risk of CVD to the same level of the normal population. Currently the incidence of FH is estimated at 1 in 240 persons in the Caucasian population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.019DOI Listing
November 2017
10 Reads

CaRe high - Cascade screening and registry for high cholesterol in Germany.

Atheroscler Suppl 2017 Nov 1;30:72-76. Epub 2017 Jun 1.

D•A•CH-Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen e.V., Hamburg, Germany; Synlab Academy, Synlab Holding Germany GmbH, Mannheim, Germany; Clinical Institut for Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria; Medical Clinic V (Nephrology, Hypertension, Rheumatology, Endocrinology, Diabetology), Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany.

Introduction: Familial hypercholesterolemia (FH) is an inherited disorder of the LDL metabolism, leading to cardiovascular disease, even at young age. This risk can be significantly lowered by early diagnosis and treatment. About 270,000 patients affected in Germany are not diagnosed correctly and only a small number is treated properly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.015DOI Listing
November 2017
37 Reads

Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolism.

Atheroscler Suppl 2017 Nov 1;30:63-71. Epub 2017 Jun 1.

Department of Internal Medicine III, University Hospital Gießen and Marburg GmbH, Gießen, Germany.

Background: Numerous healthcare studies have shown that more than 90% of all patients with dyslipidaemia are not treated adequately.

Objectives: The "Deutsche Gesellschaft zur Bekämpfung von Fettstoffwechselstörungen und ihren Folgeerkrankungen (DGFF)" [German Society of Lipidology], a non-profit professional membership organization, has already made a series of efforts to improve the care of patients suffering from dyslipidaemia. A recent outcome is the nationwide implementation and certification of Lipidological Competence Centres and Networks (LCCNs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.014DOI Listing
November 2017
20 Reads

Analysis of lipid metabolism and its impact on the risk of ischemic heart disease in patients with definite familial hypercholesterolemia.

Atheroscler Suppl 2017 Nov 1;30:56-62. Epub 2017 Jun 1.

Lipidology and Lipoprotein Apheresis Center, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.

Aim: to analyze the relationship between lipid disturbance, including lipoprotein(a) (Lp(a)) levels, and development of ischemic heart disease (IHD) in patients with familial hypercholesterolemia (FH).

Materials And Methods: 81 patients (middle age was 39.1 ± 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.008DOI Listing
November 2017
14 Reads

Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.

Atheroscler Suppl 2017 Nov 31;30:50-55. Epub 2017 May 31.

Scientific Institute for Nephrology (WiNe), Düsseldorf, Germany.

Background: In recent years the Federal Joint Committee (G-BA), a paramount decision-making body of the German health care system required a reassessment of the approval of chronic lipoprotein apheresis therapy for regular reimbursement. Since 2005 an interdisciplinary German apheresis working group has been established by members of both German Societies of Nephrology. In 2009 the working group completed the indication for lipoprotein apheresis with respect to current cardiovascular guidelines and current scientific knowledge for the registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.006DOI Listing
November 2017
5 Reads

Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?

Atheroscler Suppl 2017 Nov 1;30:44-49. Epub 2017 Jun 1.

Department of Medicine II for Nephrology, Hypertension and Vascular Risks, AGAPLESION Markus Hospital, Frankfurt, Germany.

According to current European guidelines, lipid lowering therapy for progressive cardiovascular disease including cardiovascular events has to be focused on a target level for LDL-C. In contrast for Lp(a) a threshold has to be defined with respect to the method of measurement. However, due to new lipid lowering drug developments like PCSK9-inhibitors (PCSK-9-I) a therapeutic algorithm for patients with severe hypercholesterolemia or isolated Lipoprotein(a)-hyperlipoproteinemia with progressive cardiovascular disease may be necessary to manage the use of PCSK9-I, lipoprotein apheresis (LA) or both. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.005DOI Listing
November 2017
8 Reads

Lipoprotein(a)-apheresis in the light of new drug developments.

Authors:
Anja Vogt

Atheroscler Suppl 2017 Nov 31;30:38-43. Epub 2017 May 31.

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ziemssenstrasse 1, 80336 Muenchen, Germany. Electronic address:

Elevated levels of lipoprotein(a) (Lp(a)) contribute to the risk of early and severe cardiovascular disease (CVD). Recently <50 mg/dl was recommended as the desirable level for clinical use and decision making. All established medical therapies to lower cholesterol levels have no impact on lowering Lp(a) except niacin which is all too often poorly tolerated and not obtainable everywhere. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.025DOI Listing
November 2017
4 Reads

Management of patients with statin intolerance.

Atheroscler Suppl 2017 Nov 1;30:33-37. Epub 2017 Jun 1.

Lipidology, Department of Internal Medicine III, University Hospital Dresden Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr 74, 01307 Dresden, Germany.

In recent years statins have become an established option in lipid-lowering pharmacotherapy despite the fact that statin intolerance is fairly common. When muscle pains and/or an elevation of the creatine kinase appear, the dose must be lowered in patients with slight symptoms or stopped altogether if the symptoms are more severe. When the symptoms are alleviated and creatine kinase is normalized, re-exposition can be considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.013DOI Listing
November 2017
5 Reads

ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.

Atheroscler Suppl 2017 Nov 1;30:319-325. Epub 2017 Jun 1.

Division of Nephrology, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.

Background And Aims: Cardiovascular disease is the major cause of morbidity and mortality in the world. Diabetes and its complications, such as diabetic nephropathy, dramatically increase cardiovascular risk. Association studies suggest that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthases, plays a role in the pathogenesis of diabetic nephropathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.031DOI Listing
November 2017
28 Reads

In vivo imaging of murine vasodynamics analyzing different mouse strains by optical coherence tomography.

Atheroscler Suppl 2017 Nov 31;30:311-318. Epub 2017 May 31.

Division of Vascular Endothelium and Microcirculation, Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany. Electronic address:

Background And Aims: We tried to circumvent the limitations of standard organ chamber experiments using in vivo optical coherence tomography (OCT) to analyze the vascular function of small arteries in different mouse strains.

Methods: OCT images were acquired with a two-axis galvanometer scanner head. Time series (3 frames per second, 300 × 512 pixel per frame) of cross-sectional images were analyzed with image processing software measuring the time course of vessel lumen dynamics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.023DOI Listing
November 2017
10 Reads

Impact of omega-3 fatty acids on expression of angiogenic cytokines and angiogenesis by adipose-derived stem cells.

Atheroscler Suppl 2017 Nov;30:303-310

Division of Vascular Endothelium and Microcirculation, Department of Medicine III, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. Electronic address:

Background And Aims: Human adipose-tissue derived stem cells (ADSC) are interesting novel targets in tissue engineering and regenerative medicine with pronounced angiogenic capacities. Furthermore, omega-3 fatty acids have been described to mediate cardioprotective effects, but their role in angiogenesis and vascular regeneration is not well-understood. Here, we analyzed the impact of different omega-3 fatty acids on angiogenesis by ADSCs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.040DOI Listing
November 2017
12 Reads